Insulin analogs and pregnancy

Diabetes Spectrum

Volumn 20, Issue 2, 2007, Pages 94-101

  Trujillo, Angelina L ^a  

^a SANSUM DIABETES RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN;

CONGENITAL HEART MALFORMATION; CONGENITAL MALFORMATION; DIABETES MELLITUS; DIABETIC RETINOPATHY; DOSE CALCULATION; DRUG ABSORPTION; DRUG EFFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; FETUS OUTCOME; FOOD AND DRUG ADMINISTRATION; HUMAN; HYALINE MEMBRANE DISEASE; HYDRONEPHROSIS; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LARGE FOR GESTATIONAL AGE; MACROSOMIA; MENINGOMYELOCELE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREGNANCY; PREGNANCY COMPLICATION; PREGNANCY DIABETES MELLITUS; RETINOPATHY; REVIEW; RISK FACTOR; SIDE EFFECT; SPONTANEOUS ABORTION; THERAPEUTIC ABORTION; UROGENITAL TRACT MALFORMATION;

EID: 34250702820     PISSN: 10409165     EISSN: None     Source Type: Journal    
DOI: 10.2337/diaspect.20.2.94     Document Type: Review

References (67)

1. Engelgau MM, Herman WH, Smith PJ, German RR, Aubert RE: The epidemiology of diabetes and pregnancy in the U.S., 1988. Diabetes Care 18:1029-1033, 1995
2. The DCCT Research Group: Pregnancy outcomes in the Diabetes Control and Complications Trial: Am J Obstet Gynecol 174:P1343-P1353, 1996
3. Yang J, Cummings EA, O'Connel C, Jangaard K: Fetal and neonatal outcomes of diabetic pregnancies. Obstet Gynecol 108:644-650, 2006
4. Ray JG, O'Brien TE, Chan WS: Preconception care and the risk of congenital anomalies in the offspring of women with diabetes mellitus: a meta-analysis. Q J Med 94:435-444, 2001
5. Kitzmiller JL, Gavin LA, Gin GD, Jovanovic-Peterson L, Main EK, Zigrang WD: Preconception care of diabetes: glycemic control prevents congenital anomalies. JAMA 265:731-736, 1991
6. De Veciana MD, Major CA, Morgan MA, Asrat T, Toohey JS, Lien JM, Evans AT: Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. N Engl J Med 333:1237-1241, 1995
7. Walkinshaw SA: Pregnancy in women with pre-existing diabetes: management issues. Sem Fetal Neonatal Med 10:307-315, 2005
8. Jovanovic-Peterson L, Peterson CM, Reed GF, Metzger BE, Mills JL, Knopp RH, Aarons JH: Maternal postprandial glucose levels and infant birth weight: the Diabetes in Early Pregnancy study. Am J Obstet Gynecol 164:103-111, 1991
9. Combs CA, Gunderson E, Kitzmiller JL, Gavin LA, Main EK: Relationship of fetal macrosomia to maternal postprandial glucose control during pregnancy. Diabetes Care 15:1251-1257, 1992
10. Manderson JG, Patterson CC, Hadden DR, Traub AI, Ennis C, McCance DR: Preprandial versus postprandial blood glucose monitoring in type 1 diabetic pregnancy: a randomized controlled clinical trial. Am J Obstet Gynecol 189:507-512, 2003
11. Jovanovic L, Peterson CM, Saxena BB, Dawood MY, Saudek CD: Feasibility of maintaining normal glucose profiles in insulin-dependent pregnant diabetic women. Am J Med 68:105-112, 1980
12. Buse MG, Roberts WJ, Buse J: The role of the human placenta in the transfer and metabolism of insulin. J Clin Invest 41:29-41, 1962
13. Bauman WA, Yalow RS: Transplacental passage of insulin complexed to antibody. Proc Natl Acad Sci U S A 78:4588-4590, 1981
14. Balsells M, Corcoy R, Mauricio D, Morales J, Garcia-Patterson A, Carreras G, Puig-Domingo M, de Leiva A: Insulin antibody response to a short course of human insulin therapy in women with gestational diabetes. Diabetes Care 20:1172-1175, 1997
15. Pedersen J: Weight and length of infants of diabetic mothers. Acta Endocrinol 12:330-342, 1954
16. Langer O: Fetal macrosomia: etiologic factors. Clin Obstet Gynecol 43:283-297, 2000
17. Baxley EG, Gobbo RW: Shoulder dystocia. Am Fam Phys 69:1707-1714, 2004
18. Gamson K, Chia S, Jovanovic L: Review the safety and efficacy of insulin analogs in pregnancy. J Matern-Fetal Neonat Med 15:26-34, 2004
19. Drugs for Diabetes: Treatment Guidelines from the Medical Letter. 3:57-62, 2005
20. Insulin detemir (Levemir), a new long-acting insulin. Med Lett Drug Ther 48:54-55, 2006
21. Torlone E, Gennarini A, Ricci NB, Bolli GB: Successful use of insulin glargine during entire pregnancy until delivery in six type 1 diabetic women. Eur J Obstet Gynecol Reprod Biol 24 June 2006. Epub ahead of print
22. Novolog insulin aspart (rDNA origin) injection prescribing information. Princeton, N.J., Novo Nordisk, Inc., 2007
23. Apidra (insulin glulisine [rDNA origin] injection) prescribing information. Kansas City, Mo., Aventis Pharmaceuticals, 2005
24. Hedman CA, Lindstrom T, Arnqvist HJ: Direct comparison of insulin lispro and aspart shows small differences in plasma insulin profiles after subcutaneous injection in type 1 diabetes. Diabetes Care 24:1120-1121, 2001
25. Plank J, Wutte A, Brunner G, Siebenhofer A, Semlitsch B, Sommer R, Hirschberger S, Pieber TR: A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes. Diabetes Care 25:2053-2057, 2002
26. Homko C, Deluzio A, Jimenez C, Kolaczynski JW, Boden G: Comparison of insulin aspart and lispro pharmacokinetic and metabolic effects. Diabetes Care 26:2027-2031, 2003
27. Taton J, Milicevik Z, Mozejko-Pastewka B, Bernas M, Czech A: How recombinant insulin analogs improve insulin therapy of diabetes mellitus: pathophysiology, clinical practice and recommendations. Med Sci Monit 7:848-859, 2001
28. Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, De Vincenzo A, Cordoni C, Costa E, Brunetti P, Bolli GB: Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 49:2142-2148, 2000
29. Yki-Jarvinen H, Dressier A, Ziemen M, the HOE 901/3002 Study Group: Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 23:1130-1136, 2000
30. Raskin P, Klaff L, Bergenstal R, Halle J-P, Donley D, Mecca T: A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 23:1666-1671, 2000
31. Rosenstock J, Schwartz SL, Clark CM, Park GD, Donley DW, Edwards MB: Basal insulin therapy in type 2 diabetes 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 24:631-636, 2001
32. Plank J, Bodenlenz M, Sinner F, Magnes C, Gorzer E, Regittnig W, Endahl LA, Draeger E, Zdravkovic M, Pieber TR: A double-blind, randomized dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting analogue detemir. Diabetes Care 28:1107-1112, 2005
33. Chapman TM, Perry CM: Spotlight on insulin detemir in type 1 and type 2 diabetes mellitus. Bio Drugs 19:67-69, 2005
34. De Leeuw I, Vague P, Selam J-L, Skeie S, Lang H, Draeger E, Elte JWF: Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab 7:73-81, 2005
35. Kølendorf K, Ross GP, Pavlic-Renart I, Perriello G, Philotheous A, Jendle J, Gall M-A, Heller SR: Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in type 1 diabetes. Diabet Med 23:729-735, 2006
36. Meadows M: Pregnancy and the drug dilemma. FDA Consumer Magazine. Washington, D.C., U.S. Food and Drug Administration, May-June 2001
37. Jovanovic L, Knopp RH, Haesook K, Cefalu WT, Zhu X-D, Young JL, Simpson JL, Mills JL, for the Diabetes In Early Pregnancy Study Group: Elevated pregnancy losses at high and low extremes of maternal glucose in early normal and diabetic pregnancy: evidence for a protective adaptation in diabetes. Diabetes Care 29:113-117, 2005
38. Jovanovic L, Ilic S, Pettitt DJ, Hugo K, Gutierrez M, Bowsher RR, Bastyr EJ: The metabolic and immunologic effects of insulin lispro in gestational diabetes. Diabetes Care 22:1422-1426, 1999
39. Battacharyya A, Brown S, Hughes S, Vice PA: Insulin lispro and regular insulin in pregnancy. Q J Med 94:255-260, 2001
40. Mecacci F, Carignani L, Cioni R, Bartoli E, Parretti E, La Torre P, Scarselli G, Mello G: Maternal metabolic control and perinatal outcome in women with gestational diabetes treated with regular or lispro insulin: comparison with non-diabetic pregnant women. Euro J Obstet Gynecol Reprod Biol 111:19-24, 2003
41. Persson B, Swahn ML, Hjertberg R, Hanson U, Nord E, Nordlander E, Hansson LO: Insulin lispro therapy in pregnancies complicated by type 1 diabetes mellitus. Diabetes Res Clin Pract 58:115-121, 2002
42. Masson EA, Patmore JE, Brash PD, Baxter M, Caldwell G, Gallen IW, Price PA, Vice PA, Walker JD, Lindow SW: Pregnancy outcome in type 1 diabetes mellitus treated with insulin lispro (Humalog). Diabet Med 20:46-50, 2003
43. Loukovaara S, Immonen I, Teramo KA, Kaaja R: Progression of retinopathy during pregnancy in type 1 diabetic women treated with insulin lispro. Diabetes Care 26:1193-1198, 2003
44. Cypryk K, Sobczak M, Pertynska-Marczewska M, Zawodniak-Szalapska M, Szymczak W, Wilczynski J, Lewinski A: Pregnancy complications and perinatal outcome in diabetic women treated with Humalog (insulin lispro) or regular human insulin during pregnancy. Med Sci Monit 10:129-132, 2004
45. Pettitt DJ, Ospina P, Kolaczynski J, Jovanovic L: Comparison of an insulin analogue, insulin aspart, and regular human insulin with no insulin in gestational diabetes mellitus. Diabetes Care 26:183-186, 2003
46. Holstein A, Plaschke A, Egberts EH: Use of insulin glargine during embryogenesis in a pregnant woman with type 1 diabetes. Diabet Med 20:779-780, 2003
47. Devlin JT, Hothersall L, Wilkis JL: Use of insulin glargine during pregnancy in a type 1 diabetic woman. Diabetes Care 25:1095-1096, 2002
48. Dolci M, Mori M, Baccetti F: Use of glargine insulin before and during pregnancy in a woman with type 1 diabetes and Addison's disease. Diabetes Care 28:2084-2085, 2005
49. DiMarchi RD, Chance RF, Long HB, Shields JE, Slieker LJ: Preparation of an insulin with improved pharmacokinetics relative to human insulin through consideration of structural homology with insulin-like growth factor I. Horm Res 41 (Suppl. 2):93-96, 1994
50. Janssen JA, Jacobs ML, Derkx FH, Weber RF, van der Lely AJ, Lamberts SW: Free and total IGF-I, IGFBP-I and IGFBP-3 and their relationships to the presence of diabetic retinopathy and glomerular hyperfiltration in insulin-dependent diabetes mellitus (IDDM). J Clin Endocrinol Metab 83:2809-2815, 1997
51. Kitzmiller JL, Main E, Ward B, Theiss T, Peterson DL: Insulin lispro and the development of proliferative diabetic retinopathy during pregnancy. Diabetes Care 22:874-875, 1999
52. Bhattacharyya A, Vice PA: Insulin lispro, pregnancy and retinopathy. Diabetes Care 22:2101-2102, 1999
53. Buchbinder A, Miodovnik M, McElvy S, Rosenn B, Kranias G, Khoury J, Siddiqi TA: Is insulin lispro associated with the development or progression of diabetic retinopathy during pregnancy? Am J Obstet Gynecol 183:1162-1165, 2000
54. Diamond T, Kormas N: Possible adverse fetal effect of insulin lispro. N Engl J Med 337:1009-1010, 1997
55. Idama TO, Lindow SW, French M, Massono EA: Preliminary experience with the use of insulin lispro in pregnant diabetic women. J Obstet Gynecol 21:350-351, 2001
56. Scherbaum WA, Lankisch MR, Pawlowski B, Somville T: Insulin lispro in pregnancy: retrospective analysis of 33 cases and matched controls. Exp Clin Endocrinol Diabetes 110:6-9, 2002
57. Menon RK, Cohen RM, Sperling MA, Cutfield WS, Mimouni F, Khoury JC: Transplacental passage of insulin in pregnant women with insulin-dependent diabetes mellitus: its role in fetal macrosomia. N Engl J Med 323:309-315, 1990
58. Boskovic R, Feig DS, Derewlany L, Knie B, Portnoi G, Koren G: Transfer of insulin lispro across the human placenta. Diabetes Care 26:1390-1394, 2003
59. Ozcan T, Karne A, Murphy J, Nickless N, Magriples U, Jones DC: Does lispro improve blood glucose control and birth weight? [Abstract] Obstet Gynecol 97:S41, 2001
60. Evers IM, De Valk HW, Mol BWJ, Ter Braak EWMT, Visser GHA: Macrosomia despite good glycaemic control in type 1 diabetic pregnancy: results of a nationwide study in the Netherlands. Diabetologia 45:1484-1489, 2002
61. Hofmann T, Horstmann G, Stammberger I: Evaluation of the reproductive toxicity and embryotoxicity of insulin glargine (Lantus) in rats and rabbits. Int J Toxicol 21:181-189, 2002
62. Lantus (insulin glargine [rDNA origin] injection) product information. Bridgewater, N.J., Sanofi-Aventis U.S., 2006
63. Di Cianni G, Volpe L, Lencioni C, Chatzianagnostou K, Cuccuru I, Ghio A, Benzi L, Del Prato S: Use of insulin glargine during the first weeks of pregnancy in five type 1 diabetic women. Diabetes Care 28:982-983, 2005
64. Woolderink JM, van Loon AJ, Storms F, De Heide L, Hoogenberg K: Use of insulin glargine during pregnancy in seven type 1 diabetic women. Diabetes Care 28:2394-2395, 2005
65. Graves DE, White JC, Kirk JK: The use of insulin glargine with gestational diabetes mellitus. Diabetes Care 29:411-412, 2006
66. Caronna S, Cioni F, Dall'aglio E, Arsenio L: Pregnancy and the long-acting insulin analogue: a case study. Acta Biomed Ateneo Parmense 77:24-26, 2006
67. Levemir (insulin detemir [rDNA origin] injection) prescribing information. Bagsvaerd, Denmark, Novo Nordisk A/S, 2005